CTN(300430) 上海证券·2024-02-24 16:00Investment Rating - The report assigns a "Buy" rating to Cheng Yi Tong (300430) for the first time, with a target price corresponding to a PE of 21/16/13 times for 2023-2025 [16][17] Core Views - Cheng Yi Tong has established a "one body, two wings, dual-drive" development strategy, focusing on both intelligent manufacturing and rehabilitation medical equipment businesses [7][16] - The company achieved a 33.57% YoY revenue growth and 69.68% YoY net profit growth in the first three quarters of 2023, driven by strong performance in both business segments [16][25] - In the intelligent manufacturing sector, the company is expanding into chemical synthesis, traditional Chinese medicine, and plant extraction, with new orders in chemical synthesis exceeding 180 million yuan in 2022, an 83% YoY increase [16][45] - In the rehabilitation medical equipment sector, the company is actively expanding into grassroots markets, with products entering over 5,000 domestic medical institutions and exporting to more than 30 countries [16][37] Business Performance - In 2022, the company's revenue from intelligent manufacturing and rehabilitation medical equipment accounted for 72.16% and 27.84% of total revenue, respectively, with gross margins of 30.26% and 70.86% [27] - From 2018 to 2022, the CAGR of revenue from rehabilitation medical equipment was 13.21%, higher than that of intelligent manufacturing by over 5 percentage points [27] - The company's gross profit margin and net profit margin remained stable, with 2023Q1-3 figures at 40.41% and 13.65%, respectively [28] Market and Industry Analysis - The domestic rehabilitation medical equipment market is expected to reach 67 billion yuan by 2023, driven by factors such as aging population and increasing chronic diseases [34] - The company's rehabilitation medical equipment business has a comprehensive product line covering six major fields, including pain rehabilitation, neurological rehabilitation, and orthopedic rehabilitation [35] - The company's products have obtained CE and FDA certifications, and its production capacity reaches 7,000 units/sets per year [35][37] Future Outlook - The company is expected to achieve revenue of 12.43/15.19/17.82 billion yuan in 2023-2025, with YoY growth rates of 27.61%/22.19%/17.29% [95] - Net profit is projected to be 168/221/280 million yuan in 2023-2025, with YoY growth rates of 34.73%/31.28%/26.79% [95] - The intelligent manufacturing business is expected to maintain steady growth, with revenue growth rates of 28.50%/20.00%/15.00% in 2023-2025 [76] - The rehabilitation medical equipment business is expected to grow rapidly, with revenue growth rates of 25.50%/28.00%/23.00% in 2023-2025 [76]